accreditation and certification

intended audience

This activity was developed for ophthalmologists treating patients with glaucoma.

learning objectives

Upon completion of this activity, participants should be better able to:

Distinguish the various preservatives used in topical glaucoma medications

Describe the clinical data regarding the safety and efficacy of these

preservatives and their impact on topical glaucoma medications

Evaluate risks and benefits for general and special ophthalmic populations

Incorporate this information to optimize treatment plans for patients

with glaucoma

accreditation and certification

The University of Texas Medical Branch at Galveston is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas Medical Branch at Galveston designates this education activity for a maximum of 1.0 AMA PRA Category 1 Creditstm. Physicians should only claim credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by mail following activity participation, and upon completion and return of the evaluation form to the Annenberg Center for Health Sciences. Please allow 4-6 weeks for the delivery of your statement.

disclosure

All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationship with those supporting the activity or any others whose products or services are discussed.

In accordance with the Accreditation Council for Continuing Medical Education Standards and parallel documents from other accrediting bodies the following disclosures have been made:

Eric Donnenfeld, MD

Research Support Alcon Laboratories
Allergan, Inc.
Pfizer, Inc.

Consultant Alcon Laboratories
Allergan, Inc.
Pfizer, Inc.

Robert Feldman, MD

Research Support Alcon Laboratories
Allergan, Inc.
Merck & Co., Inc.
Pfizer, Inc.

Consultant Alcon Laboratories
Allergan, Inc.
Merck & Co., Inc.
Pfizer, Inc.

Speakers Bureau Alcon Laboratories
Merck & Co., Inc.
Pfizer, Inc.

Quang Nguyen, MD

Consultant NeoMedix, Inc.

Speakers Bureau Alcon Laboratories
Allergan, Inc.
ISTA Pharmaceuticals
Pfizer, Inc.

Joel Legunn (medical writer) has nothing to disclose.

All staff at the Annenberg Center for Health Sciences at Eisenhower have nothing to disclose.

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the University of Texas Medical Branch at Galveston and the Annenberg Center and/or their agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The University of Texas Medical Branch at Galveston and the Annenberg Center disclaim all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is an enduring material and consists of a Web activity. Successful completion is achieved by reading and viewing the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1 hour.

This activity was originally released in January 2009 and is eligible for credit through December 2009.

If you need reasonable, special accommodations or have questions about access to any of our activities, please contact Gladys Medina by phone: 800-321-3690, by fax: 760-773-4550, or by e-mail: .

This activity is supported by an independent educational grant from Pfizer, Inc.